Atrius India Core FHIR Implementation Guide
0.1.0 - ci-build

Atrius India Core FHIR Implementation Guide - Local Development build (v0.1.0) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

: Atrius Drug-Drug Interaction Check

Draft as of 2026-08-30

Raw xml | Download


<PlanDefinition xmlns="http://hl7.org/fhir">
  <id value="atrius-ddi-check"/>
  <meta>
    <profile
             value="http://hl7.org/fhir/StructureDefinition/cdshooksserviceplandefinition|4.0.1"/>
  </meta>
  <language value="en"/>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p>See <code>Library/AtriusDrugInteractions</code> for pair definitions and drug-class ValueSets.</p></div>
  </text>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/cqf-cdsHooksEndpoint">
    <valueUri value="https://cds.atrius.in/cds-services/atrius-ddi-check"/>
  </extension>
  <url
       value="https://atrius.in/fhir/r4/atrius-in/PlanDefinition/atrius-ddi-check"/>
  <identifier>
    <use value="official"/>
    <value value="atrius-ddi-check"/>
  </identifier>
  <identifier>
    <system value="urn:ietf:rfc:3986"/>
    <value value="urn:oid:1.3.6.1.4.1.66219.1.34.2"/>
  </identifier>
  <version value="0.1.0"/>
  <name value="AtriusDdiCheck"/>
  <title value="Drug-Drug Interaction Check"/>
  <type>
    <coding>
      <system
              value="http://terminology.hl7.org/CodeSystem/plan-definition-type"/>
      <code value="eca-rule"/>
    </coding>
  </type>
  <status value="draft"/>
  <experimental value="true"/>
  <date value="2026-08-30T18:15:29+05:30"/>
  <publisher value="Atrius"/>
  <contact>
    <name value="Atrius"/>
    <telecom>
      <system value="url"/>
      <value value="https://atrius.in"/>
    </telecom>
  </contact>
  <description
               value="Interruptive alerts at order signing when a draft medication order interacts with an active prescription: statin + CYP3A4-inhibiting macrolide (rhabdomyolysis), warfarin + NSAID (bleeding), ACE inhibitor + potassium-sparing diuretic (hyperkalemia). Cards propose safer alternatives or monitoring."/>
  <library
           value="https://atrius.in/fhir/r4/atrius-in/Library/AtriusDrugInteractions|0.1.0"/>
  <action id="atrius-ddi-check-root">
    <title value="Drug-Drug Interaction Check"/>
    <description
                 value="A draft order interacts with an active prescription."/>
    <trigger>
      <type value="named-event"/>
      <name value="order-sign"/>
    </trigger>
    <condition>
      <kind value="applicability"/>
      <expression>
        <language value="text/cql"/>
        <expression value="Has Drug Interaction"/>
      </expression>
    </condition>
    <input>
      <type value="Patient"/>
      <profile
               value="https://atrius.in/fhir/r4/atrius-in/StructureDefinition/atrius-in-patient|0.1.0"/>
    </input>
    <input>
      <type value="MedicationRequest"/>
      <profile
               value="https://atrius.in/fhir/r4/atrius-in/StructureDefinition/atrius-in-medicationrequest|0.1.0"/>
    </input>
    <groupingBehavior value="logical-group"/>
    <action id="ddi-statin-macrolide">
      <title value="Statin + macrolide: rhabdomyolysis risk"/>
      <description
                   value="Clarithromycin and erythromycin inhibit CYP3A4 and raise statin exposure, risking myopathy and rhabdomyolysis. Consider azithromycin (minimal CYP3A4 inhibition) or hold the statin for the antibiotic course."/>
      <priority value="stat"/>
      <documentation>
        <type value="documentation"/>
        <display value="AHA statement — statin drug interactions"/>
        <url
             value="https://www.ahajournals.org/doi/10.1161/CIR.0000000000000456"/>
        <document>
          <url
               value="https://www.ahajournals.org/doi/10.1161/CIR.0000000000000456"/>
        </document>
      </documentation>
      <condition>
        <kind value="applicability"/>
        <expression>
          <language value="text/cql"/>
          <expression value="Statin Macrolide Interaction"/>
        </expression>
      </condition>
      <groupingBehavior value="logical-group"/>
      <selectionBehavior value="at-most-one"/>
      <action id="ddi-statin-macrolide-azithromycin">
        <title value="Switch to azithromycin (no CYP3A4 interaction)"/>
        <priority value="stat"/>
        <definitionCanonical
                             value="https://atrius.in/fhir/r4/atrius-in/ActivityDefinition/atrius-ad-med-azithromycin|0.1.0"/>
      </action>
    </action>
    <action id="ddi-warfarin-nsaid">
      <title value="Warfarin + NSAID: bleeding risk"/>
      <description
                   value="NSAIDs potentiate warfarin and independently injure gastric mucosa, sharply raising GI bleeding risk. Prefer paracetamol for analgesia; if an NSAID is unavoidable, add gastroprotection and increase INR monitoring."/>
      <priority value="stat"/>
      <documentation>
        <type value="documentation"/>
        <display value="Warfarin drug interactions (StatPearls)"/>
        <url value="https://www.ncbi.nlm.nih.gov/books/NBK470313/"/>
        <document>
          <url value="https://www.ncbi.nlm.nih.gov/books/NBK470313/"/>
        </document>
      </documentation>
      <condition>
        <kind value="applicability"/>
        <expression>
          <language value="text/cql"/>
          <expression value="Warfarin NSAID Interaction"/>
        </expression>
      </condition>
      <groupingBehavior value="logical-group"/>
      <selectionBehavior value="at-most-one"/>
      <action id="ddi-warfarin-nsaid-paracetamol">
        <title value="Use paracetamol for analgesia instead"/>
        <priority value="stat"/>
        <definitionCanonical
                             value="https://atrius.in/fhir/r4/atrius-in/ActivityDefinition/atrius-ad-med-paracetamol|0.1.0"/>
      </action>
    </action>
    <action id="ddi-acei-k-sparing">
      <title
             value="ACE inhibitor + potassium-sparing diuretic: hyperkalemia risk"/>
      <description
                   value="Combined ACE inhibitor and potassium-sparing diuretic therapy risks hyperkalemia, particularly with renal impairment. If co-prescription is intended, check baseline and follow-up potassium and renal function."/>
      <priority value="urgent"/>
      <documentation>
        <type value="documentation"/>
        <display
                 value="UK Kidney Association — acute hyperkalaemia guideline"/>
        <url
             value="https://ukkidney.org/health-professionals/guidelines/treatment-acute-hyperkalaemia-adults"/>
        <document>
          <url
               value="https://ukkidney.org/health-professionals/guidelines/treatment-acute-hyperkalaemia-adults"/>
        </document>
      </documentation>
      <condition>
        <kind value="applicability"/>
        <expression>
          <language value="text/cql"/>
          <expression
                      value="ACE Inhibitor Potassium Sparing Diuretic Interaction"/>
        </expression>
      </condition>
      <groupingBehavior value="logical-group"/>
      <action id="ddi-acei-k-sparing-bmp">
        <title value="Order potassium and renal function (BMP)"/>
        <priority value="urgent"/>
        <definitionCanonical
                             value="https://atrius.in/fhir/r4/atrius-in/ActivityDefinition/atrius-ad-lab-bmp|0.1.0"/>
      </action>
    </action>
  </action>
</PlanDefinition>